NCM
PCVX icon

Nantahala Capital Management’s Vaxcyte PCVX Stock Holding History

Nantahala Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.9M Buy
+238,746
New +$13M 0.51% 54

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nantahala Capital Management's PCVX Position: Q1 2026 in Review

Nantahala Capital Management opened a new position in Vaxcyte (PCVX) in Q1 2026: 238,746 shares worth $13.9M. The stake represents 0.51% of the portfolio and ranks #54 among its holdings.

336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Nantahala Capital Management held 238,746 shares of Vaxcyte worth $13.9M as of Q1 2026.
  • Vaxcyte was a new Nantahala Capital Management position in Q1 2026.
  • Vaxcyte made up 0.51% of Nantahala Capital Management's portfolio in Q1 2026, its #54 holding.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.